ADMS Historical Earnings image   This ADMS historical earnings page last updated 11/15/2021
ADMS Historical Revenue
PeriodHistorical Earnings DateGAAP
Q3 202111/10/20210.03B
Q2 20218/9/20210.02B
Q1 20215/10/20210.02B
Q4 20202/23/20210.02B
Q3 202011/5/20200.02B
Q2 20208/6/20200.02B
Q1 20205/7/20200.01B
Q4 20192/25/20200.02B
Q3 201911/7/20190.01B
Q2 20198/8/20190.01B
Q1 20195/9/20190.01B
Q4 20183/4/201913.31M
Q3 201811/1/201810.61M
Q2 20188/2/20187.57M
Q1 20185/3/20182.55M
Q4 20172/22/2018568000
Q3 201711/2/20171000
Q2 20178/8/20172000
Q1 20175/9/2017NA
Q4 20162/28/201737000
Q3 201611/3/2016138000
Q2 20168/4/2016222000
Q1 20165/10/2016175000
Q4 20153/5/2016520000
Q3 201511/12/2015768000
Q2 20158/11/2015398000
Q1 20155/13/2015226000
Q4 20143/3/201530.30M
Q3 201411/4/201421.50M
Q2 20148/7/201425.15M
Q1 20145/13/2014180000
ADMS Historical Earnings EPS
Data adjusted for ADMS split history

PeriodHistorical Earnings DateGAAP
Q3 202111/10/2021-0.430
Q2 20218/9/2021-0.270
Q1 20215/10/2021-0.360
Q4 20202/23/2021-0.640
Q3 202011/5/2020-0.420
Q2 20208/6/2020-0.370
Q1 20205/7/2020-0.590
Q4 20192/25/2020-0.830
Q3 201911/7/2019-0.990
Q2 20198/8/2019-0.900
Q1 20195/9/2019-1.080
Q4 20183/4/2019-1.06
Q3 201811/1/2018-1.22
Q2 20188/2/2018-1.26
Q1 20185/3/2018-1.35
Q4 20172/22/2018-1.27
Q3 201711/2/2017-1.04
Q2 20178/8/2017-0.93
Q1 20175/9/2017-0.72
Q4 20162/28/2017-0.68
Q3 201611/3/2016-0.66
Q2 20168/4/2016-0.78
Q1 20165/10/2016-0.65
Q4 20153/5/2016-0.58
Q3 201511/12/2015-0.81
Q2 20158/11/2015-0.78
Q1 20155/13/2015-0.69
Q4 20143/3/20150.53
Q3 201411/4/2014-0.57
Q2 20148/7/20140.88
Q1 20145/13/2014-0.67
Quotes delayed 20 minutes

Email EnvelopeFree ADMS Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts
10 Most Oversold S&P 500 Stocks
10 Most Overbought S&P 500 Stocks
10 ETFs With Stocks Insiders Are Buying
10 ETFs With Most Upside To Targets
The DividendRank Top 25
Warren Buffett Dividend Stocks
10 Cheap Dividend Stocks Under $10
10 Top DividendRank'ed Energy Stocks
The 10 Highest Yielding Preferred Stocks
The 10 Highest Yielding Preferred Stocks
The 15 Most Active S&P Call & Put Options
Adamas Pharmaceuticals (ADMS) is categorized under the Healthcare sector; to help you further research past earnings across stocks, below are some other companies in the same sector:

ADPT Past Earnings
ADTX Past Earnings
ADUS Past Earnings
ADVM Past Earnings
ADXS Past Earnings
AEMD Past Earnings
AERI Past Earnings
AFIB Past Earnings
AGEN Past Earnings
AGIO Past Earnings
What was the record high ADMS historical earnings result?
In terms of earnings or revenue, what is the best ADMS historical earnings result that Adamas Pharmaceuticals has ever posted, and when?

✔️Accepted answer: Within our data set, the highest ADMS historical earnings result was set in Q2 2014, when Adamas Pharmaceuticals posted results of 0.88/share. The most successful revenue quarter within our data set was Q4 2014 when Adamas Pharmaceuticals reported revenue of 30.30M.

What was the lowest Adamas Pharmaceuticals historical earnings result?
In terms of top line revenue or bottom line earnings per share, what was the lowest ADMS has reported, and when?

✔️Accepted answer: Within our data set, the lowest ADMS historical earnings result was set in Q1 2018, when Adamas Pharmaceuticals posted results of -1.35/share. The smallest revenue quarter within our data set was Q1 2017 when Adamas Pharmaceuticals reported revenue of NA.

On this page we presented the ADMS historical earnings date information for Adamas Pharmaceuticals. Reviewing that ADMS Historical Earnings for the company, we see that the highest historical earnings result in our data set was in Q2 2014, when ADMS posted gaap of 0.88/share. Meanwhile the lowest ADMS historical earnings result was in Q1 2018, when ADMS posted gaap of -1.35/share. Moving to Adamas Pharmaceuticalss historical revenue numbers, the largest revenue quarter in our data set was seen in Q4 2014 when ADMS reported 30.30M in revenue, while the smallest revenue quarter was Q1 2017 when ADMS reported NA in revenue.

For self directed investors doing their due diligence on ADMS or any other given stock, their research can benefit from looking into all of the Adamas Pharmaceuticals historical earnings in our data set presented side by side on one page for ease of comparison. Reviewing this historical EPS information can help when projecting future earnings per share, as well as providing important context for pondering whether the historical earnings trajectory justifies the current stock value or not. That's why we bring you to make it more convenient for investors to look into Adamas Pharmaceuticals historical earnings, or the historical earnings information for any stock in our coverage universe. In your continued due diligence investigations, we hope you check out the further links included for historical PE studies, earnings surprises history as well as next earnings dates for ADMS. Thanks for visiting, and the next time you need to research ADMS historical earnings or those of another stock, we hope our site will come to your mind as your preferred historical earnings, revenue, and EPS research resource of choice.

ADMS Historical Earnings | | Copyright © 2020 - 2021, All Rights Reserved

Nothing in is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.